{"id":18694,"date":"2024-11-20T12:07:58","date_gmt":"2024-11-20T06:37:58","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=18694"},"modified":"2024-11-20T12:11:15","modified_gmt":"2024-11-20T06:41:15","slug":"emerging-therapies-in-ards-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market","title":{"rendered":"Watch Out for the Most Promising Therapies in the Pipeline in ARDS Market"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d5e3229228d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d5e3229228d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\/#Emering_Therapies_in_the_ARDS_Market\" >Emering Therapies in the ARDS Market<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\/#Drug_EB05\" >Drug: EB05<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\/#Drug_ExoFlo_DB-001\" >Drug: ExoFlo (DB-001)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\/#Drug_MultiStem\" >Drug: MultiStem<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\/#Drug_GEn_1124\" >Drug: GEn 1124<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\/#Drug_ALT-100\" >Drug: ALT-100<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\/#Drug_STSA_1002\" >Drug: STSA 1002<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\/#Drug_TP508\" >Drug: TP508<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\/#Future_Perspectives_in_the_ARDS_Market\" >Future Perspectives in the ARDS Market<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Acute respiratory distress syndrome (ARDS)<\/strong> is a rapidly progressing condition that affects critically ill people. The major complication of ARDS is fluid leaking into the lungs, which makes breathing difficult or impossible. Shortness of breath, cough, and fever are among ARDS symptoms; in certain cases, high heart rates and rapid breathing have also been observed. Patients with ARDS may have chest pain, particularly during inhalation, and some may also have blue nails and lips owing to drastically reduced oxygen levels in the blood. <\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>In<strong> 2023, <\/strong>the<a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-ards-epidemiology-forecast\"> total incident cases of Acute Respiratory Distress Syndrome (ARDS)<\/a> in the <strong>United States<\/strong> were approximately <strong>591,000,<\/strong> representing about<strong> 62% of the total ARDS cases<\/strong> across the <strong>7MM (United States, EU4, UK, and Japan).<\/strong> The EU4 countries (Germany, France, Italy, and Spain) and the UK contributed around <strong>34%<\/strong> of the <strong>total ARDS cases<\/strong>, while <strong>Japan <\/strong>accounted for approximately <strong>4% of the market share.<\/strong><\/p>\n<\/blockquote>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-ards-market\" class=\"ek-link\">Acute respiratory distress syndrome<\/a> is treated with supportive measures such as mechanical ventilation, prevention of stress ulcers and venous thromboembolism, nutritional assistance, and therapy of the underlying damage. Low tidal volume, strong positive end-expiratory pressure, and conservative fluid management may enhance results. Diagnosing and treating any underlying infections with antibiotics that target culture sensitivities is critical. Despite decades of study, ARDS treatment options are limited. The core of management is supportive care with mechanical ventilation. There are few ARDS therapies available in the ARDS market.<\/p>\n\n\n\n<p>Other ARDS treatment options for patients include <strong>supplementary oxygen, prone posture, paralytics, fluid management, and a method known as positive end-expiratory pressure (PEEP)<\/strong> to help force fluid out of air sacs. These are used in conjunction with ongoing <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-ards-market\">ARDS treatment<\/a> of the initial illness or injury.<\/p>\n\n\n\n<p>Because persons with ARDS have a reduced ability to fight infections in their lungs, they may acquire bacterial pneumonia throughout their illness. Antibiotics are used to treat infections. Supportive care, such as intravenous fluids or nourishment, may also be required.<\/p>\n\n\n\n<p>The Food and Drug Administration granted an emergency use authorization (EUA) for the drug <strong>Actemra\/RoActemra<\/strong> (tocilizumab for the ARDS treatment of hospitalized adults and pediatric patients (2 years of age and older) receiving systemic corticosteroids and requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation) (ECMO). Current ARDS medications are only effective in treating ARDS-related inflammation; none treat reduced lung function.<\/p>\n\n\n\n<p>However, the ARDS market is expected to grow positively due to the factors such as an <strong>increase in the incident pool, the anticipated entry of emerging therapies<\/strong>, among others, in the 7MM. The increase in ARDS market size is also a consequence of a <strong>rise in awareness and disease understanding<\/strong>.<\/p>\n\n\n\n<p>As per our estimates, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-ards-market\">Acute Respiratory Distress Syndrome therapeutic market<\/a> in the <strong>7MM is projected to grow at a<\/strong> <strong>CAGR of 3.6%<\/strong>, driven by increasing disease awareness, improved diagnostics, and the introduction of emerging therapies. In <strong>2023,<\/strong> the <strong>market size<\/strong> was estimated at approximately <strong>USD 1.6 billion.<\/strong><\/p>\n\n\n\n<p>Several molecules are being evaluated and investigated by leading pharmaceutical companies such as <strong>Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, <\/strong>and others to strengthen the ARDS pipeline, thereby raising the hope for an efficacious therapy soon.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"220\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115323\/Key-Players-Working-in-the-ARDS-Treatment-Market-1024x220.png\" alt=\"Key Players Working in the ARDS Treatment Market\" class=\"wp-image-30396\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115323\/Key-Players-Working-in-the-ARDS-Treatment-Market-1024x220.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115323\/Key-Players-Working-in-the-ARDS-Treatment-Market-300x64.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115323\/Key-Players-Working-in-the-ARDS-Treatment-Market-150x32.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115323\/Key-Players-Working-in-the-ARDS-Treatment-Market-768x165.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115323\/Key-Players-Working-in-the-ARDS-Treatment-Market-1536x330.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115323\/Key-Players-Working-in-the-ARDS-Treatment-Market-2048x440.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The expected launch of <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-pipeline-insight\">emerging ARDS therapies<\/a>, such as <strong>EB05 (paridiprubart) by Edesa Biotech and Light Chain Bio, ExoFlo (DB-001) by Direct Biologics, MultiStem (HLCM051) by Healios and Nobel Pharma, GEn 1124 by GEn1E Lifesciences, ALT-100 by Aqualung Therapeutics Corp., STSA 1002 by Staidson (Beijing) Biopharmaceuticals Co., Ltd., TP508 by Chrysalis BioTherapeutics, <\/strong>and others shall further create a positive impact on the ARDS market.<\/p>\n\n\n\n<p>Apart from the molecules mentioned above<strong>, EVO-003, Sabizabulin (VERU-111), Invimestrocel, and Ibudilast, <\/strong>among others, are the other pipeline ARDS therapies expected to enter the ARDS market. Moreover, the uptake of potential emerging ARDS therapies with a better clinical profile is expected to be high since no drug is approved. Currently, several assets in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-pipeline-insight\">ARDS pipeline<\/a> are in the late and middle stages of development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Emering_Therapies_in_the_ARDS_Market\"><\/span><strong>Emering Therapies in the ARDS Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_EB05\"><\/span>Drug: EB05<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company:<\/strong> Edesa Biotech\/Light Chain Bio<\/p>\n\n\n\n<p><strong>Phase:<\/strong> Phase III<\/p>\n\n\n\n<p><strong>MoA: <\/strong>Toll-like receptor 4 antagonists<\/p>\n\n\n\n<p><strong>Special Designation:<\/strong> Fast track designation (US)<\/p>\n\n\n\n<p>EB05 (paridiprubart) is an experimental monoclonal antibody that Edesa believes could regulate the overactive and dysfunctional immune response associated with ARDS. Specifically, the drug inhibits toll-like receptor 4 (TLR4) signaling which is an important mediator of inflammation responsible for acute lung injury that is activated by SARS-CoV2, SARS-CoV1, and influenza viruses. EB05 has demonstrated safety in two clinical studies (&gt;120 patients) and was able to block LPS-induced (TLR4 agonist) IL-6 release in humans.&nbsp;<\/p>\n\n\n\n<p>In 2023, Edesa and the US FDA agreed on the primary efficacy endpoint for the Phase III trial of paridiprubart in ARDS patients with COVID-19. The drug received fast track designation. In June 2024, BARDA selected it for a government-funded Phase II trial in the US to evaluate its potential in ARDS. A separate Phase III trial of paridiprubart for ARDS due to SARS-CoV-2 is also ongoing in the US and another country.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_ExoFlo_DB-001\"><\/span>Drug: ExoFlo (DB-001)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company: <\/strong>Direct Biologics<\/p>\n\n\n\n<p><strong>Phase:<\/strong> Phase III<\/p>\n\n\n\n<p><strong>MoA:<\/strong> Immunosuppressants; Inflammation mediator modulators; Protein replacements<\/p>\n\n\n\n<p><strong>Special Designation: <\/strong>Regenerative Medicine Advanced Therapy (RMAT) (US)<\/p>\n\n\n\n<p>ExoFlo (DB-001) being developed by Direct Biologics is an extracellular signal product isolated from human bone marrow mesenchymal stem or stromal cells (BM-MSCs) that contains growth factors and extracellular vesicles including exosomes. It provides natural bioactive signals that downregulate inflammation, direct cellular communication, and upregulate tissue repair in humans. In April 2022, the US FDA awarded ExoFlo a Regenerative Medicine Advanced Therapy (RMAT) designation. In July 2022, the company initiated the evaluation of the drug in Phase III for COVID-19 moderate-to-severe ARDS.&nbsp;<\/p>\n\n\n\n<p>In April 2023, the US FDA authorized the expansion pivotal Phase III EXTINGUISH ARDS trial to evaluate the safety and efficacy of ExoFlo in the treatment of moderate-to-severe acute respiratory distress syndrome from any underlying etiology. The drug had favorable safety data and significant efficacy results from its Phase II clinical trial in hospitalized adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome, and it also reported successful results from its expanded access program in hospitalized COVID-19 patients with moderate-to-severe ARDS.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_MultiStem\"><\/span>Drug: MultiStem<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company:<\/strong> Athersys\/Healios<\/p>\n\n\n\n<p><strong>Phase: <\/strong>Phase III<\/p>\n\n\n\n<p><strong>MoA: <\/strong>Cell replacements<\/p>\n\n\n\n<p><strong>Special Designation: <\/strong>Fast Track Designation (US), RMAT Designation (US)<\/p>\n\n\n\n<p>MultiStem (HLCM051) is a patented regenerative product designed to enhance tissue repair and healing through various mechanisms, including the production of therapeutic factors in response to inflammation and tissue damage, as well as restoring immune system balance. It is being developed for acute respiratory distress syndrome (ARDS). The US FDA has granted MultiStem Cell Therapy both Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for treating ARDS. Additionally, HLCM051 has received orphan drug designation in Japan for the same indication.&nbsp;<\/p>\n\n\n\n<p>Enrollment for a pivotal Phase II\/III trial assessing MultiStem cell therapy in COVID-19-induced ARDS patients has been suspended until funding or a partnership is secured. Healios holds the global development rights for ARDS and is preparing for overseas clinical trials, including in the US, to expedite the commercialization of HLCM051 while exploring various partnership and alliance opportunities.&nbsp;<\/p>\n\n\n\n<p>In 2023, Healios reached an agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan on the trial design needed for data augmentation regarding an additional trial. Healios and Nobel Pharma have also signed a letter of intent for a development and marketing alliance for HLCM051 in Japan.&nbsp;<\/p>\n\n\n\n<p>In February 2024, Healios initiated a Phase III study in Japan involving patients with pneumonia-induced ARDS.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_GEn_1124\"><\/span>Drug: GEn 1124<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company:<\/strong> GEn1E Lifesciences<\/p>\n\n\n\n<p><strong>Phase:<\/strong> II<\/p>\n\n\n\n<p><strong>MoA: <\/strong>Mitogen-activated protein kinase 14 inhibitors<\/p>\n\n\n\n<p>GEn 1124 is an investigative small molecule drug being developed in collaboration with GEn1E Lifesciences and Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to support the development of the company&#8217;s novel therapy for acute respiratory distress syndrome (ARDS), The drug candidate is mitogen-activated protein kinase 14 inhibitors . Currently, the drug is in Phase II stage of its development for the treatment of acute respiratory distress syndrome.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_ALT-100\"><\/span>Drug: ALT-100<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company: <\/strong>Aqualung Therapeutics Corp.<\/p>\n\n\n\n<p><strong>Phase:<\/strong> II<\/p>\n\n\n\n<p><strong>MoA: <\/strong>Nicotinamide phosphoribosyltransferase inhibitors<\/p>\n\n\n\n<p>ALT-100 is a \u201cFirst in Man\u201d immune-based monoclonal antibody (mAb) being developed by Aqualung Therapeutics Corp. ALT-100 antibody is a revolutionary, next-generation antibody therapy. The humanized antibody has been developed and optimized by Fusion Antibodies\u2019 revolutionary CDRx humanization and ADD develop ability platforms. This humanized monoclonal antibody will block systemic inflammation and will improve survival in the ARDS. ALT-100 inhibits eNAMPT binding to TLR4. Currently, the drug is in the Phase II stage of clinical trial for the treatment of acute distress respiratory syndrome.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_STSA_1002\"><\/span>Drug: STSA 1002<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company: <\/strong>Staidson (Beijing) Biopharmaceuticals Co., Ltd<\/p>\n\n\n\n<p><strong>Phase:<\/strong> I\/II<\/p>\n\n\n\n<p><strong>MoA: <\/strong>Complement C5a inhibitors<\/p>\n\n\n\n<p>STSA 1002 is an investigative recombinant anti-human C5a IgG1 monoclonal antibody which acts by targeting complement C5a inhibitors C5a by specifically binding to anaphylatoxin C5a, C5a loses its ability to bind to receptors and blocks C5a-induced Biological functions, such as neutrophil chemotaxis, degranulation, and oxygen respiratory burst, etc., while not affecting C5 cleavage and the formation of membrane attack complex (MAC), retaining the bacteriolytic and bactericidal functions of the complement system, thereby achieving the treatment of viruses, etc. Severe pneumonia, acute lung injury, or acute respiratory distress syndrome caused by factors. It is administered through oral and subcutaneous route. Currently, the drug is in the Phase I\/II stage of its development for the treatment of acute respiratory distress syndrome.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_TP508\"><\/span>Drug: TP508<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company: <\/strong>Chrysalis BioTherapeutics<\/p>\n\n\n\n<p><strong>Phase: <\/strong>I\u00a0<\/p>\n\n\n\n<p><strong>MoA:<\/strong> Angiogenesis inducing agents; Apoptosis inhibitors; Cytokine modulators; Intercellular signalling peptide and protein stimulants; Nitric oxide stimulants; Osteogenesis stimulants; Signal transduction pathway modulators<\/p>\n\n\n\n<p>Chrysalis BioTherapeutics is developing TP508, a 23-amino acid peptide derived from thrombin, to treat ARDS and radiation-induced damage. TP508 promotes tissue repair by activating endothelial cells and stem cells, restoring vascular function, and reducing inflammation. Preclinical data show its potential to mitigate radiation damage and pulmonary inflammation. Supported by NIH and BARDA, TP508 is advancing under the FDA Animal Rule, with potential approval by 2027. It offers a promising approach where previous treatments have failed.<\/p>\n\n\n\n<p>In May 2024, Chrysalis BioTherapeutics was chosen to take part in the 2024 Respiratory Innovation Summit (RIS) during the American Thoracic Society Meeting in San Diego.<\/p>\n\n\n\n<p>The company has obtained FDA IND approval to advance into human clinical trials and has launched a Phase I Safety\/PK trial. Following this, additional trials involving ARDS patients will be conducted as funding becomes available.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Perspectives_in_the_ARDS_Market\"><\/span><strong>Future Perspectives in the ARDS Market <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The ARDS market is expected to be dominated by high-priced agents such as stem cell therapies and other pipeline candidates with a better clinical profile. Several molecules are being evaluated and investigated by various pharmaceutical companies to strengthen the ARDS pipeline and raise the prospect of effective therapy shortly. The <a href=\"https:\/\/www.delveinsight.com\/blog\/ards-epidemiological-trends-and-risk-factors\">increased ARDS prevalence<\/a> encourages drug research and development because it is likely to provide an appropriate environment for newer products to be profitable. Because no drug has been approved, demand for potential emerging therapies with a better clinical profile is expected to be high in the ARDS market in the future. Hence, due to all these factors, the <a href=\"https:\/\/www.delveinsight.com\/blog\/ards-market-outlook\">ARDS treatment market<\/a> is expected to witness an upsurge in the coming years.\u00a0<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-ards-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/20110611\/Acute-Respiratory-Distress-Syndrome-Market-Outlook-1024x194.png\" alt=\"Acute Respiratory Distress Syndrome Market Outlook\" class=\"wp-image-30378\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/20110611\/Acute-Respiratory-Distress-Syndrome-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/20110611\/Acute-Respiratory-Distress-Syndrome-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/20110611\/Acute-Respiratory-Distress-Syndrome-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/20110611\/Acute-Respiratory-Distress-Syndrome-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/20110611\/Acute-Respiratory-Distress-Syndrome-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/20110611\/Acute-Respiratory-Distress-Syndrome-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Acute respiratory distress syndrome (ARDS) is a rapidly progressing condition that affects critically ill people. The major complication of ARDS is fluid leaking into the lungs, which makes breathing difficult or impossible. Shortness of breath, cough, and fever are among ARDS symptoms; in certain cases, high heart rates and rapid breathing have also been observed. [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30395,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[12149,12146,19679,16819,19678,19660,19677],"industry":[17225],"therapeutic_areas":[17243],"class_list":["post-18694","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-acute-respiratory-distress-syndrome-2","tag-ards","tag-ards-clinical-trials","tag-ards-market","tag-ards-pipeline","tag-ards-prevalence","tag-ards-therapies","industry-pharmaceutical","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Watch Out for Top Pipeline Therapies Making an Impact in ARDS Market<\/title>\n<meta name=\"description\" content=\"As no approved drug in the ARDS market, uptake of emerging therapies is expected to high. Currently, several assets are in ARDS pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Watch Out for Top Pipeline Therapies Making an Impact in ARDS Market\" \/>\n<meta property=\"og:description\" content=\"As no approved drug in the ARDS market, uptake of emerging therapies is expected to high. Currently, several assets are in ARDS pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-20T06:37:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-20T06:41:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115238\/Watch-Out-for-the-Most-Promising-Therapies-in-the-Pipeline-in-ARDS-Market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Watch Out for Top Pipeline Therapies Making an Impact in ARDS Market","description":"As no approved drug in the ARDS market, uptake of emerging therapies is expected to high. Currently, several assets are in ARDS pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market","og_locale":"en_US","og_type":"article","og_title":"Watch Out for Top Pipeline Therapies Making an Impact in ARDS Market","og_description":"As no approved drug in the ARDS market, uptake of emerging therapies is expected to high. Currently, several assets are in ARDS pipeline.","og_url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-11-20T06:37:58+00:00","article_modified_time":"2024-11-20T06:41:15+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115238\/Watch-Out-for-the-Most-Promising-Therapies-in-the-Pipeline-in-ARDS-Market.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market","url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market","name":"Watch Out for Top Pipeline Therapies Making an Impact in ARDS Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115238\/Watch-Out-for-the-Most-Promising-Therapies-in-the-Pipeline-in-ARDS-Market.png","datePublished":"2024-11-20T06:37:58+00:00","dateModified":"2024-11-20T06:41:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"As no approved drug in the ARDS market, uptake of emerging therapies is expected to high. Currently, several assets are in ARDS pipeline.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-in-ards-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115238\/Watch-Out-for-the-Most-Promising-Therapies-in-the-Pipeline-in-ARDS-Market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115238\/Watch-Out-for-the-Most-Promising-Therapies-in-the-Pipeline-in-ARDS-Market.png","width":466,"height":284},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/20115238\/Watch-Out-for-the-Most-Promising-Therapies-in-the-Pipeline-in-ARDS-Market-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">acute respiratory distress syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ARDS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ARDS clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ARDS Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ARDS pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ARDS prevalence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ARDS therapies<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">acute respiratory distress syndrome<\/span>","<span class=\"advgb-post-tax-term\">ARDS<\/span>","<span class=\"advgb-post-tax-term\">ARDS clinical trials<\/span>","<span class=\"advgb-post-tax-term\">ARDS Market<\/span>","<span class=\"advgb-post-tax-term\">ARDS pipeline<\/span>","<span class=\"advgb-post-tax-term\">ARDS prevalence<\/span>","<span class=\"advgb-post-tax-term\">ARDS therapies<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 20, 2024","modified":"Updated on Nov 20, 2024"},"absolute_dates_time":{"created":"Posted on Nov 20, 2024 12:07 pm","modified":"Updated on Nov 20, 2024 12:11 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=18694"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18694\/revisions"}],"predecessor-version":[{"id":30400,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18694\/revisions\/30400"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30395"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=18694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=18694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=18694"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=18694"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=18694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}